
Sage Therapeutics Delivers Q1 2025 Results, Showcases Pipeline Progress and Strategic Developments
Sage Therapeutics Reports First Quarter 2025 Financial Results, Showcases Strong Momentum for ZURZUVAE and Pipeline Advancements Sage Therapeutics, Inc. (Nasdaq: SAGE) has announced its financial results for the first quarter ended March 31, 2025, highlighting solid progress in the commercialization…












